Abbott to Launch the First “Glucose Sport Biosensor”
Abbott announced plans to launch the novel “Libre Sense Glucose Sport Biosensor” (view website), which is intended to provide glucose readings and actionable insights to athletes with and without diabetes. Libre Sense has already received CE Mark, and Abbott said the product will be launched “in the coming weeks” to eight European countries via Abbott’s non-exclusive partnership with Phil Southerland’s Supersapiens (view Supersapiens website). Below, FENIX provides a brief overview of the Libre Sense Glucose Sport Biosensor and implications to the overall glucose-sensing market.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.